Dynamically-adaptive live therapeutic agents and methods of use thereof
This disclosure provides microbes engineered to detect virulent and spore states of pathogens and release an appropriate therapeutic response accordingly and compositions and methods of use of the same.
1. A method of treating Clostridium difficile ( C. diff ) infection in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a viable genetically engineered Lactobacillus or Lactococcus bacterium comprising a dual pathogen state detection system, the dual pathogen detection system comprising:
(a) a first sensor for detection of a large clostridial toxin secreted by a virulent form of C. diff , wherein the first sensor is operatively connected to a virulent secretion system, wherein the virulent secretion system produces one or more agents in an encapsulated shell; and
(b) a second sensor for detection of a cell surface protein on a spore form of C. diff , wherein the second sensor is operatively connected to a spore secretion system, wherein the spore secretion system produces an encapsulated agent;
and wherein the method results in fewer or less severe symptoms of the C. diff infection compared to a subject receiving a conventional therapy.
2. The method of claim 1 , wherein the first sensor is an antibody or a functionally active epitope-binding fragment thereof that immunospecifically binds to the toxin, and the second sensor is an antibody or an epitope-binding fragment thereof that immunospecifically binds to the cell surface protein.
3. The method of claim 2 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.
4. The method of claim 1 , wherein the large clostridial toxin is C. diff toxin A (TcdA) or C. diff toxin B (TcdB).
5. The method of claim 1 , wherein the cell surface protein is a spore coat protein of C. diff.
6. The method of claim 5 , wherein the spore coat protein is BclA glycoprotein or cysteine-rich protein CdeC.
7. The method of claim 1 , wherein the one or more agents in the encapsulated shell is a bacteriocin.
8. The method of claim 7 , wherein the bacteriocin is selected from the group consisting of colicin, diffocin, pyocin, and rhuricin 17.
9. The method of claim 1 , wherein the one or more agents in the encapsulated shell is an autolysin, an endolysin, an antimicrobial peptide, an antitoxin, or any combination thereof.
10. The method of claim 1 , wherein the encapsulated agent induces germination of the spore.
11. The method of claim 1 , wherein the encapsulated agent is a bile salt or a protease.